Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells

Yan-Fang Tao1, Jun Lu, Xiao-Juan Du

  • 1Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.

BMC Cancer
|December 27, 2012
PubMed
Abstract

Insights

YM155 effectively inhibits SK-NEP-1 cell proliferation and induces apoptosis, showing significant antitumor activity in xenograft models. This study reveals YM155

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Survivin is a key regulator of mitosis and apoptosis, often overexpressed in tumors.
  • YM155 is a novel targeted agent designed to suppress survivin.
  • SK-NEP-1 cells serve as a model for evaluating YM155's antitumor potential.

Purpose of the Study:

  • To assess the antitumor activity of YM155 against SK-NEP-1 cells.
  • To investigate the molecular mechanisms underlying YM155's effects.
  • To explore potential new therapeutic targets for YM155 treatment.

Main Methods:

  • In vitro and in vivo cell proliferation assays (MTT, nude mice xenografts).
  • Apoptosis detection via Annexin V/propidium iodide staining and flow cytometry.
  • Gene expression profiling using real-time PCR arrays and Ingenuity Pathway Analysis (IPA).

Main Results:

  • YM155 dose-dependently inhibited SK-NEP-1 cell proliferation and induced apoptosis.
  • Significant reduction in SK-NEP-1 xenograft tumor volume and weight was observed.
  • Gene expression analysis revealed significant upregulation and downregulation of key genes involved in cell death pathways, with IPA highlighting cell death and cancer mechanisms.

Conclusions:

  • YM155 demonstrates significant apoptosis-inducing and proliferation-inhibiting effects on SK-NEP-1 cells.
  • YM155 shows efficacy in reducing xenograft tumor growth with minimal side effects.
  • IPA analysis suggests potential new targets like NR3C1 and dexamethasone for YM155 therapy, offering insights into its molecular mechanism.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...